The deal sees HGS Europe’s founders Graeme and Angela McFarlane bring the market access services of HGS to the IMS Health UK team.
Together the McFarlanes bring more than 40 years’ experience in marketing, sales, consulting and senior management roles in the pharmaceutical industry at companies such as GlaxoSmithKline, AstraZeneca, Bristol-Myers Squibb and MSD, and also in the pharmaceutical outsourcing, healthcare data and technology and private hospital sectors.
Established in 1998, HGS Europe works with clients to engage with NHS payers and secure patient access to innovative medicines, working across rare diseases with orphan drugs and in therapeutic areas such as oncology, cystic fibrosis, diabetes, respiratory and mental health.
For the full story click IMS Health
IMS Health is the world’s leading information, services and technology company dedicated to making healthcare perform better.
By applying cutting-edge analytics and proprietary application suites hosted on the IMS One intelligent cloud, the company connects more than 10 petabytes of complex healthcare data on diseases, treatments, costs and outcomes to enable our clients to run their operations more efficiently.
Drawing on information from 100,000 suppliers, and on insights from more than 40 billion healthcare transactions processed annually, IMS Health’s 9,000+ expert resources drive results for over 5,000 healthcare clients globally.
Customers include pharmaceutical, medical device and consumer health manufacturers and distributors, providers, payers, government agencies, policymakers, researchers and the financial community.